Stock BMND.F BIOMIND LABS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biomind Labs Inc.

Equities

BMND.F

CA0907021012

Biotechnology & Medical Research

End-of-day quote OTC Markets
Other stock markets
 06:00:00 2024-04-03 pm EDT 		5-day change 1st Jan Change
0.11 USD 0.00% Intraday chart for Biomind Labs Inc. 0.00% +10.00%
2023 Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications CI
2023 Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 80 27.36
Enterprise Value (EV) 1 77.77 27.34
P/E ratio -17.8 x -9.17 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -23,532,521 x -9,351,910 x
EV / FCF -94,659,106 x -26,030,617 x
FCF Yield -0% -0%
Price to Book 36.5 x -111 x
Nbr of stocks (in thousands) 74,762 74,762
Reference price 2 1.070 0.3660
Announcement Date 3/31/22 3/31/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022
Net sales - - -
EBITDA - -3.399 -2.926
EBIT 1 -36.68 -3.428 -2.935
Operating Margin - - -
Earnings before Tax (EBT) 1 -36.68 -4.332 -2.986
Net income 1 -36.68 -4.332 -2.986
Net margin - - -
EPS 2 -0.8996 -0.0601 -0.0399
Free Cash Flow - -0.8451 -1.051
FCF margin - - -
FCF Conversion (EBITDA) - - -
FCF Conversion (Net income) - - -
Dividend per Share - - -
Announcement Date 6/29/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022
Net Debt - - -
Net Cash position - 2.23 0.02
Leverage (Debt/EBITDA) - - -
Free Cash Flow - -0.85 -1.05
ROE (net income / shareholders' equity) - -432% -307%
ROA (Net income/ Total Assets) - -168% -140%
Assets 1 - 2.586 2.13
Book Value Per Share 2 -0 0.0300 -0
Cash Flow per Share - 0.0300 0
Capex - 0.04 -
Capex / Sales - - -
Announcement Date 6/29/21 3/31/22 3/31/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOMIND LABS INC. Stock Biomind Labs Inc.
+10.00% 8.22M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.56% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+11.99% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.36% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.59% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.61% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.85% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+9.10% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BMND.F Stock
  4. Financials Biomind Labs Inc.